Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DoldánMartelli2013 - A Mathematical Model for the Rational Design of Chimeric Ligands in Selective Drug Therapies

ABSTRACT: This model attempts to provide a mathematical framework for describing the dynamics of receptor-drug complex formation of chimeric drugs.

SUBMITTER: Johannes Meyer

PROVIDER: MODEL1907310001 | BioModels | 2024-12-21

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MODEL1907310001?filename=Dold%C3%A1nMartelli2013.cps	Other
	MODEL1907310001?filename=Dold%C3%A1nMartelli2013.xml	Xml

Items per page:

1 - 2 of 2

Publications

A mathematical model for the rational design of chimeric ligands in selective drug therapies.

Doldán-Martelli V V Guantes R R Míguez D G DG

CPT: pharmacometrics & systems pharmacology 20130213

Chimeric drugs with selective potential toward specific cell types constitute one of the most promising forefronts of modern Pharmacology. We present a mathematical model to test and optimize these synthetic constructs, as an alternative to conventional empirical design. We take as a case study a chimeric construct composed of epidermal growth factor (EGF) linked to different mutants of interferon (IFN). Our model quantitatively reproduces all the experimental results, illustrating how chimeras ...[more]

PMID: 23887616

Similar Datasets

A mathematical model for the rational design of chimeric ligands in selective drug therapies.

Project description: Not available

| S-EPMC3600755 | biostudies-literature

Elucidating drug mechanistics and resistance in HER2-positive breast cancer cell lines by mathematical modeling

Project description:Advancing precision medicine in the field of cancer is still curbed by the fact that a rational basis to predict treatment outcome is missing. To unravel the mechanism behind targeted drugs (trastuzumab, pertuzumab, erlotinib), mathematical modeling employing ordinary differential equations (ODE) was combined with wet-lab experimentation. Experimentation relied on systematic perturbation experiments to monitor the signaling-response towards drugs in the context of EGF signaling in the HER2+ cell lines SKBR3 and HCC1954.

2016-12-31 | GSE55891 | GEO

DoldánMartelli2013 - A Mathematical Model for the Rational Design of Chimeric Ligands in Selective Drug Therapies

Project description: Not available

| MODEL1907310001 | biostudies-other

Transcriptomic RNAseq drug screen in cerebrocortical cultures; towards novel neurogenetic disease therapies.

Project description:Rare monogenic diseases affect millions worldwide; although over 4,500 rare disease genotypes are known, disease-modifying drugs are available for only 5% of them. The sheer number of these conditions combined with their rarity precludes traditional costly drug discovery programs. An economically viable alternative is to repurpose established drugs for rare diseases. Many genetic diseases result from increased or decreased protein activity and identification of clinically approved drugs which moderate this pathogenic dosage holds therapeutic potential. To identify such agents for neurogenetic diseases, we have generated genome-wide transcriptome profiles of mouse primary cerebrocortical cultures grown in the presence of 218 blood brain barrier penetrant clinic-tested drugs. RNAseq and differential expression analyses were used to generate transcriptomic profiles; therapeutically relevant drug-gene interactions related to rare neurogenetic diseases identified in this fashion were further analyzed by qRT-PCR, western blot and immunofluorescence. We have created a transcriptome-wide searchable database for easy access to the gene expression data resulting from the cerebrocortical drug screen (Neuron Screen) and have mined this data to identify a novel link between thyroid hormone and expression of the peripheral neuropathy associated gene Pmp22. Our results demonstrate the utility of cerebrocortical cultures for transcriptomic drug screening, and the database we have created will foster further discovery of novel links between over 200 clinic-tested blood brain barrier penetrant drugs and genes related to diverse neurologic conditions.

2018-09-07 | GSE110256 | GEO

Cancer Cell’s Seven Achilles Heels: Considerations for design of anti-cancer drug combinations.

Project description:Loss of function screens using shRNA and CRISPR are routinely used to identify genes that modulate responses of tumor cells to anti-cancer drugs. Here, by integrating GSEA and CMAP analyses of multiple published shRNA screens, we identified a core set of pathways that affect responses to multiple drugs with diverse mechanisms of action. This suggests that these pathways represent “weak points” or “Achilles heels”, whose mild disturbance should make cancer cells vulnerable to a variety of treatments. These “weak points” include proteasome, protein synthesis, RNA splicing, RNA synthesis, cell cycle, Akt-mTOR, and tight junction-related pathways. Therefore, inhibitors of these pathways are expected to sensitize cancer cells to a variety of drugs. This hypothesis was tested by analyzing the diversity of drugs that synergize with FDA-approved inhibitors of the proteasome, RNA synthesis, and Akt-mTOR pathways. Indeed, the quantitative evaluation indicates that inhibitors of any of these signaling pathways can synergize with a more diverse set of pharmaceuticals, compared to compounds inhibiting targets distinct from the “weak points” pathways. Our findings described here imply that inhibitors of the “weak points” pathways should be considered as primary candidates in a search for synergistic drug combinations. We used microarray to identify genetic interaction partners of 2 drugs

2025-01-06 | GSE221858 | GEO

Regulated control of gene therapies by drug induced splicing

Project description:RNA Seq datasets from HEK293 cells treated with 25nM LMI070 To date, gene therapies for human application rely on engineered promoters that cannot be finely controlled. Here, we report a universal switch element that allows precise control for gene replacement or gene silencing after exposure to a small molecule. Importantly, these small molecule inducers are in human use, are orally bioavailable when given to animals or humans, and can reach both peripheral tissues and the brain. Moreover, the switch system (Xon) does not require the co-expression of any regulatory proteins. Using Xon, translation of desired elements for controlled gene replacement or editing machinery occurs after a single oral dose, and the robustness of expression can be controlled by drug dose and with repeated drug exposure. The ability of Xon to provide temporal control of protein expression can be adapted to cell biology applications and animal studies. Additionally, due to the oral bioavailability and safety of the drugs employed, the Xon switch provides an unprecedented opportunity to refine gene therapies for more appropriate human application.

2021-07-22 | GSE176527 | GEO

An Integrative Informatics Approach to Identify Drug Targets and Therapies for Chronic Allograft Injury after Kidney Transplantation

Project description:We performed a meta-analysis of biopsy and peripheral blood samples from publicly available microarray datasets in GEO using a two-step meta-analysis method. Our in-house 22 microarray dataset is one of the datasets. We identified 85 immune-related genes that were associated with CAI. We then sought to discover novel therapeutic relationships between drug compounds and CAI through cMAP, a large-scale integration of public gene expression data for drugs and disease. We proposed that drugs that have a potentially therapeutic effect will be able to reverse the differential expression of the 85 CAI-specific gene set during drug exposure in a modeled cell line. We selected two drugs for in vivo and in vitro validations, kaempferol and esculetin, two plant-derived compounds that were ranked at the top of the 1,309 compounds.

2016-12-31 | GSE74313 | GEO

Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.

Project description: Not available

| S-EPMC6943517 | biostudies-literature

Mathematical modeling of the microtubule detyrosination/tyrosination cycle for cell-based drug screening design.

Project description: Not available

| S-EPMC9236252 | biostudies-literature

Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.

Project description: Not available

| S-EPMC9061988 | biostudies-literature